作者
Enli Liu,David Marín,Pinaki P. Banerjee,Homer A. Macapinlac,Philip A. Thompson,Rafet Basar,Lucila Nassif Kerbauy,Bethany J Overman,Peter F. Thall,Mecit Kaplan,Vandana Nandivada,Indresh Kaur,Ana Nunez Cortes,Kai Cao,May Daher,Chitra Hosing,Evan N. Cohen,Partow Kebriaei,Rohtesh S. Mehta,Sattva S. Neelapu,Yago Nieto,Michael Wang,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani
摘要
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has shown remarkable clinical efficacy in B-cell cancers. However, CAR T cells can induce substantial toxic effects, and the manufacture of the cells is complex. Natural killer (NK) cells that have been modified to express an anti-CD19 CAR have the potential to overcome these limitations.
个性的紫菜
cctv18
null
luna
maox1aoxin
Singularity
ppg123
小小
newfat
酷波er
Jasper
脑洞疼
赘婿
Leonardi
田様
慕青
我可不会
shinysparrow
优雅山灵
pcr163
皖公网安备34019202002308
